BRPI0808791A2 - derivados tricíclicos de isoquinolina para tratamento de obesidade - Google Patents
derivados tricíclicos de isoquinolina para tratamento de obesidadeInfo
- Publication number
- BRPI0808791A2 BRPI0808791A2 BRPI0808791A BRPI0808791A BRPI0808791A2 BR PI0808791 A2 BRPI0808791 A2 BR PI0808791A2 BR PI0808791 A BRPI0808791 A BR PI0808791A BR PI0808791 A BRPI0808791 A BR PI0808791A BR PI0808791 A2 BRPI0808791 A2 BR PI0808791A2
- Authority
- BR
- Brazil
- Prior art keywords
- tricyclic
- obesity treatment
- isoquinoline derivatives
- isoquinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0700611 | 2007-03-13 | ||
US202907P | 2007-11-05 | 2007-11-05 | |
PCT/EP2008/053002 WO2008110598A1 (en) | 2007-03-13 | 2008-03-13 | Tricyclic isoquinoline derivatives for treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0808791A2 true BRPI0808791A2 (pt) | 2017-05-02 |
Family
ID=39462457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0808791A BRPI0808791A2 (pt) | 2007-03-13 | 2008-03-13 | derivados tricíclicos de isoquinolina para tratamento de obesidade |
Country Status (10)
Country | Link |
---|---|
US (1) | US8138333B2 (pt) |
EP (1) | EP2134714A1 (pt) |
JP (1) | JP2010520917A (pt) |
CN (1) | CN101631787A (pt) |
AU (1) | AU2008225753A1 (pt) |
BR (1) | BRPI0808791A2 (pt) |
CA (1) | CA2679346A1 (pt) |
EA (1) | EA016592B1 (pt) |
NZ (1) | NZ579360A (pt) |
WO (1) | WO2008110598A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124600B2 (en) | 2008-05-29 | 2012-02-28 | Albany Molecular Research, Inc. | 5-HT3 receptor modulators, methods of making, and use thereof |
WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
WO2012106448A1 (en) * | 2011-02-02 | 2012-08-09 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
JP6198715B2 (ja) * | 2012-03-06 | 2017-09-20 | 武田薬品工業株式会社 | 三環性化合物 |
US10675283B2 (en) | 2017-03-24 | 2020-06-09 | University Of South Florida | Compositions and methods for white to beige adipogenesis |
CN109180687A (zh) * | 2018-08-31 | 2019-01-11 | 山东轩德医药科技有限公司 | 一种瑞卡帕步中间体的制备方法 |
CN111961047A (zh) * | 2020-08-19 | 2020-11-20 | 南通大学 | 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法 |
CN115925658B (zh) * | 2022-11-21 | 2024-02-27 | 常州佳德医药科技有限公司 | 一种2-氨基乙基呋喃的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795451A (fr) * | 1972-02-23 | 1973-08-16 | Pfizer | Agents hypoglycemiants aza indoliques tricycliques |
US3950343A (en) * | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
EP0773942A1 (en) | 1994-07-26 | 1997-05-21 | Pfizer Inc. | 4-indole derivatives as serotonin agonists and antagonists |
US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
WO2000034242A1 (en) | 1998-12-11 | 2000-06-15 | Virginia Commonwealth University | Selective 5-ht6 receptor ligands |
MXPA03003397A (es) | 2000-10-20 | 2004-06-30 | Biovitrum Ab | N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia. |
BR0311593A (pt) * | 2002-06-05 | 2005-04-26 | Hoffmann La Roche | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc |
-
2008
- 2008-03-13 EP EP08717746A patent/EP2134714A1/en not_active Withdrawn
- 2008-03-13 JP JP2009553146A patent/JP2010520917A/ja not_active Withdrawn
- 2008-03-13 WO PCT/EP2008/053002 patent/WO2008110598A1/en active Application Filing
- 2008-03-13 US US12/075,979 patent/US8138333B2/en not_active Expired - Fee Related
- 2008-03-13 CA CA002679346A patent/CA2679346A1/en not_active Abandoned
- 2008-03-13 CN CN200880008061A patent/CN101631787A/zh active Pending
- 2008-03-13 BR BRPI0808791A patent/BRPI0808791A2/pt not_active IP Right Cessation
- 2008-03-13 AU AU2008225753A patent/AU2008225753A1/en not_active Abandoned
- 2008-03-13 EA EA200970849A patent/EA016592B1/ru not_active IP Right Cessation
- 2008-03-13 NZ NZ579360A patent/NZ579360A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US8138333B2 (en) | 2012-03-20 |
EA016592B1 (ru) | 2012-06-29 |
JP2010520917A (ja) | 2010-06-17 |
NZ579360A (en) | 2011-06-30 |
EP2134714A1 (en) | 2009-12-23 |
CA2679346A1 (en) | 2008-09-18 |
CN101631787A (zh) | 2010-01-20 |
AU2008225753A1 (en) | 2008-09-18 |
EA200970849A1 (ru) | 2010-04-30 |
US20080293694A1 (en) | 2008-11-27 |
WO2008110598A1 (en) | 2008-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0819076A2 (pt) | aparelho para tratamento de água | |
BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
BRPI0813533A2 (pt) | Purificação de conjugado | |
DK2405869T3 (da) | Fedmebehandling | |
BRPI0812155A2 (pt) | derivados de espiroindolinona | |
BRPI0817935A2 (pt) | Derivados de biarila | |
BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
DK2182863T3 (da) | Åbningsdilatator | |
BRPI0817870A2 (pt) | dispositivo para tratamento de aneurisma | |
BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
BRPI0812518A2 (pt) | Derivados de indazolamida | |
BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
BRPI0812803A2 (pt) | Dessalinização | |
BRPI0821129A2 (pt) | Métodos para a inibição de cicatrização | |
BRPI0813670A2 (pt) | Compostos para tratamento | |
BRPI0808791A2 (pt) | derivados tricíclicos de isoquinolina para tratamento de obesidade | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
BRPI0814718A2 (pt) | Derivados de isoxazol-imidazol | |
BRPI0812040A2 (pt) | Indicações para terapia de anti-il-i-beta | |
BRPI1010025A2 (pt) | dispositivo para esmiralhamento de cames | |
BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
BRPI0811478A2 (pt) | Compostos de morphinan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |